Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 235

1.

FUSE Binding Protein 1 Facilitates Persistent Hepatitis C Virus Replication in Hepatoma Cells by Regulating Tumor Suppressor p53.

Dixit U, Pandey AK, Liu Z, Kumar S, Neiditch MB, Klein KM, Pandey VN.

J Virol. 2015 Aug;89(15):7905-21. doi: 10.1128/JVI.00729-15. Epub 2015 May 20. Erratum in: J Virol. 2017 Nov 14;91(23 ):.

2.

Fuse binding protein antagonizes the transcription activity of tumor suppressor protein p53.

Dixit U, Liu Z, Pandey AK, Kothari R, Pandey VN.

BMC Cancer. 2014 Dec 8;14:925. doi: 10.1186/1471-2407-14-925.

3.

Hepatitis C virus core protein inhibits tumor suppressor protein promyelocytic leukemia function in human hepatoma cells.

Herzer K, Weyer S, Krammer PH, Galle PR, Hofmann TG.

Cancer Res. 2005 Dec 1;65(23):10830-7.

4.

Decreased Expression of Fructose-1,6-bisphosphatase Associates with Glucose Metabolism and Tumor Progression in Hepatocellular Carcinoma.

Hirata H, Sugimachi K, Komatsu H, Ueda M, Masuda T, Uchi R, Sakimura S, Nambara S, Saito T, Shinden Y, Iguchi T, Eguchi H, Ito S, Terashima K, Sakamoto K, Hirakawa M, Honda H, Mimori K.

Cancer Res. 2016 Jun 1;76(11):3265-76. doi: 10.1158/0008-5472.CAN-15-2601. Epub 2016 Apr 6.

5.

Hepatitis C Virus-Induced Upregulation of MicroRNA miR-146a-5p in Hepatocytes Promotes Viral Infection and Deregulates Metabolic Pathways Associated with Liver Disease Pathogenesis.

Bandiera S, Pernot S, El Saghire H, Durand SC, Thumann C, Crouchet E, Ye T, Fofana I, Oudot MA, Barths J, Schuster C, Pessaux P, Heim MH, Baumert TF, Zeisel MB.

J Virol. 2016 Jun 24;90(14):6387-6400. doi: 10.1128/JVI.00619-16. Print 2016 Jul 15.

6.

Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.

Wei S, Xiong M, Zhan DQ, Liang BY, Wang YY, Gutmann DH, Huang ZY, Chen XP.

Carcinogenesis. 2012 Mar;33(3):538-47. doi: 10.1093/carcin/bgr319. Epub 2012 Jan 5.

PMID:
22226916
7.

Protein kinase R modulates c-Fos and c-Jun signaling to promote proliferation of hepatocellular carcinoma with hepatitis C virus infection.

Watanabe T, Hiasa Y, Tokumoto Y, Hirooka M, Abe M, Ikeda Y, Matsuura B, Chung RT, Onji M.

PLoS One. 2013 Jul 2;8(7):e67750. doi: 10.1371/journal.pone.0067750. Print 2013.

8.

Hepatitis C virus core protein overcomes H2O2-induced apoptosis by downregulating p14 expression via DNA methylation.

Seo YL, Heo S, Jang KL.

J Gen Virol. 2015 Apr;96(Pt 4):822-32. doi: 10.1099/vir.0.000032. Epub 2014 Dec 22.

PMID:
25535325
9.

Correlation of TP53 mutations with HCV positivity in hepatocarcinogenesis: identification of a novel TP53 microindel in hepatocellular carcinoma with HCV infection.

Long J, Wang Y, Li M, Tong WM, Jia JD, Huang J.

Oncol Rep. 2013 Jul;30(1):119-24. doi: 10.3892/or.2013.2430. Epub 2013 Apr 26.

PMID:
23624687
10.

Hepatic expression of the proliferative marker Ki-67 and p53 protein in HBV or HCV cirrhosis in relation to dysplastic liver cell changes and hepatocellular carcinoma.

Koskinas J, Petraki K, Kavantzas N, Rapti I, Kountouras D, Hadziyannis S.

J Viral Hepat. 2005 Nov;12(6):635-41.

PMID:
16255765
11.

The Differential Immunohistochemical Expression of p53, c-Jun, c-Myc, and p21 Between HCV-related Hepatocellular Carcinoma With and Without Cirrhosis.

Abdou AG, Abd-Elwahed M, Badr M, Helmy M, Soliman EA, Maher D.

Appl Immunohistochem Mol Morphol. 2016 Feb;24(2):75-87. doi: 10.1097/PAI.0000000000000155.

PMID:
25710583
12.

Focal adhesion kinase (FAK) mediates the induction of pro-oncogenic and fibrogenic phenotypes in hepatitis C virus (HCV)-infected cells.

Alisi A, Arciello M, Petrini S, Conti B, Missale G, Balsano C.

PLoS One. 2012;7(8):e44147. doi: 10.1371/journal.pone.0044147. Epub 2012 Aug 28.

13.

Bromodomain containing protein represses the Ras/Raf/MEK/ERK pathway to attenuate human hepatoma cell proliferation during HCV infection.

Zhang Q, Wei L, Yang H, Yang W, Yang Q, Zhang Z, Wu K, Wu J.

Cancer Lett. 2016 Feb 1;371(1):107-16. doi: 10.1016/j.canlet.2015.11.027. Epub 2015 Nov 24.

14.

Hepatitis C virus NS3 protein modulates the biological behaviors of malignant hepatocytes by altering the expression of host cell microRNA.

Zhang J, Ishigaki Y, Takegami T.

Mol Med Rep. 2015 Oct;12(4):5109-15. doi: 10.3892/mmr.2015.4041. Epub 2015 Jul 3.

PMID:
26151503
15.

Infection with hepatitis C virus depends on TACSTD2, a regulator of claudin-1 and occludin highly downregulated in hepatocellular carcinoma.

Sekhar V, Pollicino T, Diaz G, Engle RE, Alayli F, Melis M, Kabat J, Tice A, Pomerenke A, Altan-Bonnet N, Zamboni F, Lusso P, Emerson SU, Farci P.

PLoS Pathog. 2018 Mar 14;14(3):e1006916. doi: 10.1371/journal.ppat.1006916. eCollection 2018 Mar.

16.

Complex interactions between microRNAs and hepatitis B/C viruses.

Fan HX, Tang H.

World J Gastroenterol. 2014 Oct 7;20(37):13477-92. doi: 10.3748/wjg.v20.i37.13477. Review.

17.

Hepatocellular carcinoma: molecular interactions between hepatitis C virus and p53 in hepatocarcinogenesis.

Anzola M, Burgos JJ.

Expert Rev Mol Med. 2003 Nov 19;5(28):1-16. doi: 10.1017/S1462399403006926. Review.

PMID:
14987403
18.

Overexpression of the far upstream element binding protein 1 in hepatocellular carcinoma is required for tumor growth.

Rabenhorst U, Beinoraviciute-Kellner R, Brezniceanu ML, Joos S, Devens F, Lichter P, Rieker RJ, Trojan J, Chung HJ, Levens DL, Zörnig M.

Hepatology. 2009 Oct;50(4):1121-9. doi: 10.1002/hep.23098.

19.

Cellular Gene Expression during Hepatitis C Virus Replication as Revealed by Ribosome Profiling.

Gerresheim GK, Bathke J, Michel AM, Andreev DE, Shalamova LA, Rossbach O, Hu P, Glebe D, Fricke M, Marz M, Goesmann A, Kiniry SJ, Baranov PV, Shatsky IN, Niepmann M.

Int J Mol Sci. 2019 Mar 15;20(6). pii: E1321. doi: 10.3390/ijms20061321.

20.

GP73 represses host innate immune response to promote virus replication by facilitating MAVS and TRAF6 degradation.

Zhang X, Zhu C, Wang T, Jiang H, Ren Y, Zhang Q, Wu K, Liu F, Liu Y, Wu J.

PLoS Pathog. 2017 Apr 10;13(4):e1006321. doi: 10.1371/journal.ppat.1006321. eCollection 2017 Apr. Erratum in: PLoS Pathog. 2018 Mar 13;14 (3):e1006938.

Supplemental Content

Support Center